Literature DB >> 21435165

25. Ischemic pain in the extremities and Raynaud's phenomenon.

Jacques Devulder1, Hans van Suijlekom, Robert van Dongen, Sudhir Diwan, Nagy Mekhail, Maarten van Kleef, Frank Huygen.   

Abstract

Two important groups of disorders result from an insufficient blood supply to the extremities: critical vascular disease and the Raynaud's phenomenon. The latter can be subdivided into a primary and a secondary type. Critical ischemic disease is often caused by arteriosclerosis due to hypertension or diabetes. Primary Raynaud's is idiopathic and will be diagnosed as such if underlying systemic pathology has been excluded. Secondary Raynaud's is often a manifestation of a systemic disease. It is essential to try to establish a diagnosis as soon as possible in order to influence the evolution of the disease. A sympathetic nerve block can be considered in patients with critical ischemic vascular disease after extensive conservative treatment, preferably in the context of a study (2B±). If this has insufficient effect, spinal cord stimulation can be considered in a selected patient group (2B±). In view of the degree of invasiveness and the costs involved, this treatment should preferably be applied in the context of a study and with the use of transcutaneous pO(2) measurements. In case of primary Raynaud's, life style changes are the first step. Sympathectomy can be considered as a treatment of Raynaud's phenomenon (2C+), but only after multidisciplinary evaluation of the patient and in close consultation with the patient's rheumatologist, vascular surgeon or internist.
© 2011 The Authors. Pain Practice © 2011 World Institute of Pain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21435165     DOI: 10.1111/j.1533-2500.2011.00460.x

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  7 in total

Review 1.  Spinal cord stimulation for chronic limb ischemia.

Authors:  Joseph J Naoum; Elias J Arbid
Journal:  Methodist Debakey Cardiovasc J       Date:  2013-04

2.  Treatment of Raynaud's phenomenon with botulinum toxin type A.

Authors:  Xiaolong Zhang; Yong Hu; Zhiyu Nie; Ye Song; Yougui Pan; Ying Liu; Lingjing Jin
Journal:  Neurol Sci       Date:  2015-01-24       Impact factor: 3.307

Review 3.  Spinal cord stimulation for intractable chronic pain.

Authors:  Leonardo Kapural
Journal:  Curr Pain Headache Rep       Date:  2014-04

4.  Long Acting Liposomal Bupivacaine for Percutaneous Sympathetic Stellate Ganglion Blockade: A Technical Note.

Authors:  Adnan I Qureshi; Muhammad A Waqas; Vikram Jadhav; Muhammad A Saleem; Jeff Campbell; Shawn S Wallery
Journal:  J Vasc Interv Neurol       Date:  2017-10

5.  Hypoxia-induced sensitisation of TRPA1 in painful dysesthesia evoked by transient hindlimb ischemia/reperfusion in mice.

Authors:  Kanako So; Yuna Tei; Meng Zhao; Takahito Miyake; Haruka Hiyama; Hisashi Shirakawa; Satoshi Imai; Yasuo Mori; Takayuki Nakagawa; Kazuo Matsubara; Shuji Kaneko
Journal:  Sci Rep       Date:  2016-03-17       Impact factor: 4.379

Review 6.  "Evidence-Based Interventional Pain Medicine According to Clinical Diagnoses": Update 2018.

Authors:  Frank Huygen; Jan Willem Kallewaard; Maurits van Tulder; Koen Van Boxem; Kris Vissers; Maarten van Kleef; Jan Van Zundert
Journal:  Pain Pract       Date:  2019-05-02       Impact factor: 3.183

7.  Successful Spinal Cord Stimulation for Necrotizing Raynaud's Phenomenon in COVID-19 Affected Patient: The Nightmare Comes Back.

Authors:  Mariateresa Giglio; Angela Preziosa; Martina Rekatsina; Omar Viswanath; Ivan Urits; Giustino Varrassi; Antonella Paladini; Filomena Puntillo
Journal:  Cureus       Date:  2021-04-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.